|
業務類別
|
Biotechnology |
|
業務概覽
|
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc. |
| 公司地址
| 100 SE, 2nd Street, Suite 2000, No.1009, Miami, FL, USA, 33131 |
| 電話號碼
| +1 786 396-6723 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.telomirpharma.com |
| 員工數量
| 5 |
| Mr. Alan Weichselbaum, C.P.A.,M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
-- |
17/03/2026 |
| Mr. Erez Aminov |
Chairman of the Board and Chief Executive Officer |
美元 106.14K |
17/03/2026 |
|
|
| Mr. Erez Aminov |
Chairman of the Board and Chief Executive Officer |
17/03/2026 |
| Mr. Edward MacPherson |
Independent Director |
17/03/2026 |
| Mr. Matthew Pratt Whalen, C.P.A. |
Independent Director |
17/03/2026 |
| Dr. Matthew Paul Del Giudice, M.D. |
Independent Director |
17/03/2026 |
|
|
|
|
